Histogenics, a regenerative medicine company, plans to hit the public markets today at a price-per-share that's lower than initial expectations.
Histogenics is slated to roll out its initial public offering today, but the starting price per share is below initial expectations set by the Massachusetts regenerative medicine company.
Plans now call for an flotation of more than 5.9 million shares at $11 per share, with an expected take of about $57.2 million.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1FMFYv5
Cap comentari:
Publica un comentari a l'entrada